If you are interested in the future of pharmaceutical risk management, you might want to start by reading a 15-year-old report.
In an interview on the evolution of FDA’s Risk Evaluation & Mitigation Strategies, Amgen Inc. Executive Director-Global Regulatory Policy Paul Seligman brought with him a copy of the 1999 report by FDA’s task force on risk management for medical products